US Patent

US8236962 — Metalloenzyme inhibitor compounds

Composition of Matter · Assigned to Viamet Pharmaceuticals Inc · Expires 2031-04-22 · 5y remaining

Vulnerability score 18/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects metalloenzyme inhibitor compounds and methods for treating diseases, disorders, or symptoms mediated by metalloenzymes.

USPTO Abstract

The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

Drugs covered by this patent

Patent Metadata

Patent number
US8236962
Jurisdiction
US
Classification
Composition of Matter
Expires
2031-04-22
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Viamet Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.